HTR1E
ENSG00000168830
Target class
GPCR
Chromosome
6
Approved drugs
3
Clinical candidates (approved and in development)
3
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- 5-HT1E
- Target name
- HTR1E
- Gene name
- 5-hydroxytryptamine receptor 1E
- Gene symbol
- HTR1E
- Protein name
- 5-hydroxytryptamine receptor 1E (5-HT-1E) (5-HT1E) (S31) (Serotonin receptor 1E)
- Gene biotype
- Protein coding
- Gene family
- 5-hydroxytryptamine receptors, G protein-coupled
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 11
- Highest tissue expression
- 5.01
- Tissue specificity (Gini)
- 0.78
- Tissue specificity (tau)
- 0.906
- KEGG gene identifiers
- hsa:3354
- Protein interaction confidence
- 0.77285
- Protein interaction partners
- 20
- R-HSA-390666
- R-HSA-418594
- End position
- 87017155
- Start position
- 86936662
- Chromosome
- 6
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- PubMed 14744596
- PubMed 1513320
- PubMed 1608964
- PubMed 1733778
- PubMed 21422162
- Tissue specificity (tau)
- 0.90615
- Expression inequality (Gini)
- 0.779912
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 5.01
- Brain - Cortex
- 3.49
- Brain - Nucleus accumbens (basal ganglia)
- 2.7
- Brain - Anterior cingulate cortex (BA24)
- 2.22
- Brain - Cerebellar Hemisphere
- 2.22
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)5.01
- Brain - Cortex3.49
- Brain - Nucleus accumbens (basal ganglia)2.7
- Brain - Anterior cingulate cortex (BA24)2.22
- Brain - Cerebellar Hemisphere2.22
- Brain - Caudate (basal ganglia)2.13
- Ovary1.83
- Brain - Cerebellum1.71
- Brain - Putamen (basal ganglia)1.46
- Stomach1.4
- Brain - Hypothalamus1.02
- Testis0.75
- Brain - Amygdala0.73
- Brain - Hippocampus0.66
- Esophagus - Muscularis0.47
- Esophagus - Gastroesophageal Junction0.42
- Uterus0.42
- Thyroid0.36
- Cervix - Endocervix0.24
- Brain - Substantia nigra0.23
- Cervix - Ectocervix0.1
- Brain - Spinal cord (cervical c-1)0.08
- Colon - Sigmoid0.08
- Pituitary0.06
- Skin - Not Sun Exposed (Suprapubic)0.04
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0007187
- GO:0007193
- GO:0007198
- GO:0007268
Cellular components
- GO:0005886
- GO:0001586
- GO:0004930
- GO:0004993
- GO:0005515
- GO:0051378
Related records
Trials (1,337)
- "Extended" (Alternate Day) Antipsychotic Dosing
- "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
- [11C]Yohimbine PET Study of alpha2-AR
- 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
- 12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
- 12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)
- 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
- 24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study
- 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
- 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
- 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
- 3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects
- 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)
- 40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)
- 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
- 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)
- 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)
- A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
Drugs (32)
- Amisulpride Serotonin (5-HT) receptor antagonist
- Asenapine
- Chlorophenylpiperazine
- Clozapine
- Dexfenfluramine Serotonin (5-HT) receptor agonist
- Dexfenfluramine hydrochloride Serotonin (5-HT) receptor agonist
- Dihydroergotamine
- Donitriptan
- Eletriptan
- Ergonovine
- Ergotamine
- Fluspirilene
- Mebufotenin
- Metergoline
- Methylergonovine
- Methysergide
- Metitepine
- Naratriptan
- Olanzapine
- Quetiapine